Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study

被引：77

作者：

Lee, Kang-Moon ^{[1
]}

Jeen, Yoon Tae ^{[2
]}

Cho, Ju Yeon ^{[3
]}

Lee, Chang Kyun ^{[4
]}

Koo, Ja-Seol ^{[2
]}

Park, Dong Il ^{[5
]}

Im, Jong Pil ^{[6
]}

Park, Soo Jung ^{[7
]}

Kim, You Sun ^{[8
]}

Kim, Tae Oh ^{[10
]}

Lee, Suck-Ho ^{[11
]}

Jang, Byung Ik ^{[12
]}

Kim, Ji Won ^{[6
]}

Park, Young Sook ^{[14
]}

Kim, Eun-Soo ^{[13
]}

Choi, Chang Hwan ^{[9
]}

Kim, Hyo Jong ^{[4
]}

机构：

[1] Catholic Univ Korea, St Vincents Hosp, Dept Internal Med, Suwon, South Korea

[2] Korea Univ, Dept Internal Med, Seoul 136705, South Korea

[3] Sungkyunkwan Univ, Seoul Samsung Hosp, Dept Internal Med, Seoul, South Korea

[4] Kyung Hee Univ, Dept Internal Med, Seoul, South Korea

[5] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Internal Med, Seoul, South Korea

[6] Seoul Natl Univ, Dept Internal Med, Seoul, South Korea

[7] Yonsei Univ, Dept Internal Med, Seoul 120749, South Korea

[8] Inje Univ, Dept Internal Med, Seoul Paik Hosp, Seoul, South Korea

[9] Chung Ang Univ, Dept Internal Med, Seoul 156756, South Korea

[10] Inje Univ, Dept Internal Med, Haeundae Paik Hosp, Pusan, South Korea

[11] Soonchunghyang Univ, Cheonan Hosp, Dept Internal Med, Cheonan, South Korea

[12] Yeungnam Univ, Dept Internal Med, Taegu, South Korea

[13] Keimyung Univ, Dept Internal Med, Taegu, South Korea

[14] Eulji Univ, Dept Internal Med, Taejon, South Korea

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2013年 / 28卷 / 12期

关键词：

efficacy; infliximab; predictor of response; safety; ulcerative colitis; INFLAMMATORY-BOWEL-DISEASE; C-REACTIVE PROTEIN; SONGPA-KANGDONG DISTRICT; REMISSION; CONSENSUS; OUTCOMES; SEOUL;

D O I：

10.1111/jgh.12324

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

Background/AimsInfliximab is currently used for the treatment of moderate-to-severe ulcerative colitis (UC) with an inadequate response to conventional agents. The efficacy and safety of infliximab in Korean patients with UC were assessed. MethodsThis was a retrospective multicenter study including all adult patients who received at least one infliximab infusion for UC. Short- and long-term clinical outcomes and adverse events of infliximab therapy were evaluated, and predictors of response were identified. ResultsA total of 134 UC patients were included. The indications for infliximab therapy were acute severe UC in 28%, steroid-dependency in 38%, and steroid-refractoriness in 33%, respectively. The rates of clinical response and remission were 87% and 45% at week 8. In multivariate analysis, we found significant predictors of clinical remission at week 8: immunomodulator-naive (odds ratio [OR]=4.89, 95% confidence interval [CI]: 1.44-16.66, P=0.01), hemoglobin11.5g/dL (OR=4.47, 95% CI: 1.48-13.45, P=0.008), C-reactive protein3mg/dL (OR=4.77, 95% CI: 1.43-15.94, P=0.01), and response at week 2 (OR=20.54, 95% CI: 2.40-175.71, P=0.006). Long-term clinical response and remission rates were 71% and 52%, respectively, and mucosal healing was the only factor influencing long-term response. Adverse events related to infliximab occurred in 15% of patients, and most of them were mild and transient. ConclusionsInfliximab is effective and safe in the treatment of active UC in Korea. No history of previous immunomodulator use and high baseline C-reactive protein are independent predictors of good response.

引用

页码：1829 / 1833

页数：5

共 27 条

[1]

Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis [J].